CN114028444A - Probiotic composition and application thereof in relieving depression and reducing fat accumulation - Google Patents
Probiotic composition and application thereof in relieving depression and reducing fat accumulation Download PDFInfo
- Publication number
- CN114028444A CN114028444A CN202111469754.8A CN202111469754A CN114028444A CN 114028444 A CN114028444 A CN 114028444A CN 202111469754 A CN202111469754 A CN 202111469754A CN 114028444 A CN114028444 A CN 114028444A
- Authority
- CN
- China
- Prior art keywords
- parts
- bifidobacterium animalis
- bpl1
- composition
- hypericin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 239000006041 probiotic Substances 0.000 title claims abstract description 84
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 84
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 77
- 238000009825 accumulation Methods 0.000 title claims abstract description 13
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 157
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 157
- 239000000284 extract Substances 0.000 claims abstract description 91
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 82
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 80
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims abstract description 57
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229940005608 hypericin Drugs 0.000 claims abstract description 56
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims abstract description 56
- 230000036651 mood Effects 0.000 claims abstract description 9
- 101100111651 Serratia marcescens smeA gene Proteins 0.000 claims description 16
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 6
- 235000019789 appetite Nutrition 0.000 claims description 6
- 230000036528 appetite Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000035899 viability Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 101150117627 bpl1 gene Proteins 0.000 claims 18
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 229940076279 serotonin Drugs 0.000 description 10
- 239000003674 animal food additive Substances 0.000 description 9
- 239000002778 food additive Substances 0.000 description 9
- 235000013373 food additive Nutrition 0.000 description 9
- 235000013402 health food Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000036186 satiety Effects 0.000 description 6
- 235000019627 satiety Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 4
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 3
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- -1 aromatic amino acid Chemical class 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241000546188 Hypericum Species 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- VOPQEGAWBQLJEW-HKSTYAHRSA-N (3R,5R)-1,3,4,5-tetrahydroxy-2-[(E)-3-phenylprop-2-enoyl]cyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C([C@@H](O)C1O)C(=O)\C=C\c1ccccc1)C(O)=O VOPQEGAWBQLJEW-HKSTYAHRSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000546193 Clusiaceae Species 0.000 description 1
- 101150090997 DLAT gene Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012628 flowing agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 125000002444 phloroglucinyl group Chemical class [H]OC1=C([H])C(O[H])=C(*)C(O[H])=C1[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a probiotic composition which is characterized by comprising bifidobacterium animalis and hypericum perforatum extract; or comprises Bifidobacterium animalis and hypericin. Can relieve depression, improve mood, and reduce fat accumulation.
Description
Technical Field
The invention relates to a probiotic composition, in particular to application of the probiotic composition in relieving depression and reducing fat accumulation.
Background
The neurotransmitter 5-hydroxytryptamine (5-HT) regulates collective mood and diet, whereas tryptophan is an amino acid precursor of 5-HT and also largely influences diet behavior. Tryptophan (TRP), also known as α -amino- β -indole propionic acid, is an aromatic amino acid metabolite, has a wide range of physiological functions in the aspects of regulating growth and feeding, mood and behavior, immune response, etc., is one of essential amino acids for the human body, cannot be synthesized by the human body, and must be obtained from diet. When TRP is absent, the gut immunity and microflora of the human body are affected, stimulating the accumulation of dietary fat.
The gut microbiota is a complex micro-ecosystem that not only has a major impact on the development of obesity and metabolic diseases, but also plays an important role in mental health disorders including depression, anxiety and social behavior through the "brain-gut axis". In the high-throughput screening of caenorhabditis elegans, researchers find that the strain CECT8145(BPL1) is an effective probiotic bacterium, can reduce fat deposition and takes energy homeostasis and tryptophan metabolism as targets; and regulating the central nervous system, thereby affecting mood related to satiety, anxiety, depression, and the like.
Hypericum perforatum belonging to Hypericum of Guttiferae, which is a perennial herb, contains chemical components such as hypericin, hyperforin and flavonoids, and the raw materials and extracts are recorded in the European pharmacopoeia, United states pharmacopoeia and Korean pharmacopoeia at the same time. The traditional Chinese medicine composition is widely used for research on treatment of depression, has fewer side effects than most other anti-depression prescription medicines, and also has antibacterial and antiviral properties.
The herba Hyperici perforati extract mainly contains flavonoids (6-8%, mainly quercetin and its glycosides such as hyperoside, rutin, isoquercitrin, and quercitrin), phloroglucinol derivatives (0.2-4%, hyperforin and its homologues), naphthodianthrones (0.06-0.4%, hypericin, pseudohypericin, etc.), and small amount of chlorogenic acid, caffeoylquinine, cinnamoylquinic acid, etc. The clinical common dosage form is ethanol (50-80%) or methanol (50-80%) extract of Hypericum perforatum. The total hypericin (expressed as hypericin) should be in the range of 0.10-0.30%, the content of flavonoids (in terms of rutin) is not less than 6.0%, and the maximum content of hyperforin is 6.0%. According to statistics, the hypericum perforatum extract in the market has the hypericin content of 0.16-0.32%; the content of hyperforin is 1.5-4.4%; the total flavone content is 6-8%.
In the prior art, the hypericum perforatum extract is reported to be used for relieving depression and reducing fat accumulation, for example, the traditional Chinese medicine composition disclosed in the patent WO2021093091A1 is composed of 40-80 parts of hypericum perforatum extract, 10-40 parts of acanthopanax extract and 2-20 parts of moutan bark extract and is used for regulating depression mood. CN100563454C discloses a product containing Hypericum perforatum extract, which can achieve the effect of losing weight by drinking.
Most of the components aim at gastrointestinal peristalsis, promote defecation, block absorption and the like, but the problems, namely the emotion of a human body and the emotion of food, are not fundamentally solved. Most people eat too much because of the lower serotonin content in the brain and lack of timely release of satiety signaling factors. Therefore, the whole effect is not ideal, and the composition product with high efficiency is difficult to form, so that patients have obvious body feeling after using the composition product.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a probiotic composition which comprises the following components in parts by weight: comprises Bifidobacterium animalis and Hypericum perforatum extract.
Further, the bifidobacterium animalis is bifidobacterium animalis BPL 1.
Further, the bifidobacterium animalis contains inactivated bifidobacterium animalis and/or non-inactivated bifidobacterium animalis.
Further, the bifidobacterium animalis is inactivated by heating, ultraviolet irradiation and chemical treatment; preferably, the cells are heat-inactivated. The heat-inactivated cells may be those which are collected after completion of the culture and then thermally killed, or they may be collected after the cells in the culture are made into the thermally killed cells without temporarily separating the cells from the culture.
Further, the composition contains 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericum perforatum extract; further, 1-8 parts of bifidobacterium animalis BPL1 and 1-8 parts of hypericum perforatum extract; further, 1-5 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericum perforatum extract; further, 1-3 parts of bifidobacterium animalis BPL1 and 1-3 parts of hypericum perforatum extract; furthermore, the bifidobacterium animalis BPL1 accounts for 1.8 parts, and the hypericum perforatum extract accounts for 1 part.
Further, the bacterial viability of the bifidobacteria in the composition is greater than 1 hundred million per gram of the composition, further greater than 10 hundred million per gram of the composition, further greater than 100 hundred million per gram of the composition, further greater than 500 hundred million per gram of the composition, further greater than 1000 hundred million per gram of the composition.
Furthermore, hypericin content in the hypericum perforatum extract is greater than 0.01%, further greater than 0.1%, further greater than 0.3%, further greater than 1%, further greater than 10%.
Further, the composition contains 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericin; further, 10-100 parts of bifidobacterium animalis BPL1 and 1-10 parts of hypericin; further, 50-100 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericin; further, the bifidobacterium animalis BPL1 is 60 parts, and hypericin is 1 part.
Further, the composition may or may not contain fillers/carriers/additives.
The invention also provides a probiotic composition, which comprises bifidobacterium animalis and hypericin.
Further, the bifidobacterium animalis is bifidobacterium animalis BPL 1.
Further, the bifidobacterium animalis contains inactivated bifidobacterium animalis and/or non-inactivated bifidobacterium animalis.
Further, the bifidobacterium animalis is inactivated by heating, ultraviolet irradiation and chemical treatment; preferably, the cells are heat-inactivated. The heat-inactivated cells may be those which are collected after completion of the culture and then thermally killed, or they may be collected after the cells in the culture are made into the thermally killed cells without temporarily separating the cells from the culture.
Further, the bacterial viability of the bifidobacteria in the composition is greater than 1 hundred million per gram of the composition, further greater than 10 hundred million per gram of the composition, further greater than 100 hundred million per gram of the composition, further greater than 500 hundred million per gram of the composition, further greater than 1000 hundred million per gram of the composition.
Furthermore, hypericin content in the hypericum perforatum extract is greater than 0.01%, further greater than 0.1%, further greater than 0.3%, further greater than 1%, further greater than 10%.
Further, the composition contains 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericin; further, 10-100 parts of bifidobacterium animalis BPL1 and 1-10 parts of hypericin; further, 50-100 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericin; further, the bifidobacterium animalis BPL1 is 60 parts, and hypericin is 1 part.
Further, the composition may or may not contain fillers/carriers/additives.
The invention also provides a product containing the probiotic composition, wherein the composition comprises animal bifidobacterium, hypericum perforatum extract or hypericin.
The product of the composition can be in various dosage forms, including but not limited to common dosage forms of medicines, such as powder, suppository, gel, oral liquid, hard capsules and soft capsules, and can also be common dosage forms of health-care food and dietary supplements, such as beverage, solid beverage, soft beverage, hard capsules, soft capsules, multilayer hard capsules, dissolved beans, freeze-dried powder, milk beans, chocolate, soft sweets with fillings, chocolate with fillings, tea beverage and cold-extracted coffee.
The cells of the present invention may be treated with or without microencapsulation.
The invention provides a preparation method of a probiotic composition, which comprises the step of mixing animal bifidobacterium with hypericum perforatum extract and/or hypericin.
In one embodiment, the product of the invention is prepared by the following steps: optionally granulating or non-granulating the material to be controlled to the moisture index required by production, mixing the raw materials, optionally adding additives required by the material, tabletting, and coating (enteric coating) or not coating. The adjuvants include sweetener such as maltitol, anticaking agent such as silicon dioxide and magnesium stearate, acidity regulator, and binder such as mono-diglycerol fatty acid.
In another embodiment, the product of the present invention is prepared by the following steps: optionally granulating or non-granulating the material to be controlled in water content index to the water content index required by production, mixing the bacteria and the extract, optionally adding a flowing agent required by the material, filling the capsule, optionally selecting unqualified filled capsules, and then coating (enteric coating) or not coating, and optionally filling the coated capsules into an inner packaging material according to the required specification and quantity of the package. The auxiliary materials are magnesium stearate, calcium phosphate, maltodextrin and the like.
The invention also provides application of the probiotic composition in medicaments, health-care foods, feeds, feed additives and food additives for resisting depression, improving mood, reducing appetite, controlling weight, reducing fat accumulation, inhibiting obesity, improving insulin sensitivity and reducing blood fat and blood pressure. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract. Further, the bifidobacterium animalis is bifidobacterium animalis BPL 1.
Further, the bifidobacterium animalis contains inactivated bifidobacterium animalis and/or non-inactivated bifidobacterium animalis.
Further, the bifidobacterium animalis is inactivated by heating, ultraviolet irradiation and chemical treatment; preferably, the cells are heat-inactivated. The heat-inactivated cells may be those which are collected after completion of the culture and then thermally killed, or they may be collected after the cells in the culture are made into the thermally killed cells without temporarily separating the cells from the culture.
Further, the composition contains 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericum perforatum extract; further, 1-8 parts of bifidobacterium animalis BPL1 and 1-8 parts of hypericum perforatum extract; further, 1-5 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericum perforatum extract; further, 1-3 parts of bifidobacterium animalis BPL1 and 1-3 parts of hypericum perforatum extract; furthermore, the bifidobacterium animalis BPL1 accounts for 1.8 parts, and the hypericum perforatum extract accounts for 1 part.
Further, the bacterial viability of the bifidobacteria in the composition is greater than 1 hundred million per gram of the composition, further greater than 10 hundred million per gram of the composition, further greater than 100 hundred million per gram of the composition, further greater than 500 hundred million per gram of the composition, further greater than 1000 hundred million per gram of the composition.
Furthermore, hypericin content in the hypericum perforatum extract is greater than 0.01%, further greater than 0.1%, further greater than 0.3%, further greater than 1%, further greater than 10%.
Further, the composition contains 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericin; further, 10-100 parts of bifidobacterium animalis BPL1 and 1-10 parts of hypericin; further, 50-100 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericin; further, the bifidobacterium animalis BPL1 is 60 parts, and hypericin is 1 part.
Further, the composition may or may not contain fillers/carriers/additives.
The invention also provides a probiotic composition, which comprises bifidobacterium animalis and hypericin.
Further, the bifidobacterium animalis is bifidobacterium animalis BPL 1.
Further, the bifidobacterium animalis contains inactivated bifidobacterium animalis and/or non-inactivated bifidobacterium animalis.
Further, the bifidobacterium animalis is inactivated by heating, ultraviolet irradiation and chemical treatment; preferably, the cells are heat-inactivated. The heat-inactivated cells may be those which are collected after completion of the culture and then thermally killed, or they may be collected after the cells in the culture are made into the thermally killed cells without temporarily separating the cells from the culture.
Further, the bacterial viability of the bifidobacteria in the composition is greater than 1 hundred million per gram of the composition, further greater than 10 hundred million per gram of the composition, further greater than 100 hundred million per gram of the composition, further greater than 500 hundred million per gram of the composition, further greater than 1000 hundred million per gram of the composition.
Furthermore, hypericin content in the hypericum perforatum extract is greater than 0.01%, further greater than 0.1%, further greater than 0.3%, further greater than 1%, further greater than 10%.
Further, the composition contains 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericin; further, 10-100 parts of bifidobacterium animalis BPL1 and 1-10 parts of hypericin; further, 50-100 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericin; further, the bifidobacterium animalis BPL1 is 60 parts, and hypericin is 1 part.
Further, the composition may or may not contain fillers/carriers/additives.
Interpretation of terms
As used herein, "dead bacteria" are inactivated bacteria. In the absence of other indications, the dead cells are killed cells of bifidobacterium animalis BPL 1.
"Bifidobacterium animalis BPL 1", as used herein, is a strain that is undergoing commercialization and can be purchased in a conventional manner. Wherein said strain is deposited at 14/05/12 in Parc scientific Universal de Valencia, c/Catedr a tic agglomeration i n Ecardino, 9,46980 Paterna-Valentia, Spain the collecci agglomeration viscosity (spread Type Culture Collection-CECT) under the entry number CECT8145, according to the terms of the Budapest treat Tree. Bifidobacterium animalis BPL1 is also known as bifidobacterium animalis CECT 8145; there are reports of the use of CECT8145 probiotic in the treatment and/or prevention of atopic dermatitis, and CN105849248B reports of the use of CECT8145 probiotic in the treatment of overweight.
Detailed Description
The present invention will be further described with reference to the following examples for facilitating understanding of those skilled in the art, and the description of the embodiments is not intended to limit the present invention.
Example 1
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part.
Example 2
A probiotic composition comprises 1 part of Bifidobacterium animalis BPL1 and 100 parts of herba Hyperici perforati extract.
Example 3
A probiotic composition comprises 100 parts of Bifidobacterium animalis BPL1 and 1 part of herba Hyperici perforati extract.
Example 4
A probiotic composition comprises 1 part of Bifidobacterium animalis BPL1 and 5 parts of herba Hyperici perforati extract.
Example 5
A probiotic composition comprises 5 parts of Bifidobacterium animalis BPL1 and 1 part of herba Hyperici perforati extract.
Example 6
A probiotic composition comprises Bifidobacterium animalis BPL1 60 parts and hypericin 1 part.
Example 7
A probiotic composition comprises 100 parts of Bifidobacterium animalis BPL1 and 1 part of hypericin.
Example 8
A probiotic composition comprises 1 part of Bifidobacterium animalis BPL1 and 100 parts of hypericin.
Example 9
A probiotic composition comprises 50 parts of Bifidobacterium animalis BPL1 and 1 part of hypericin.
Example 10
A probiotic composition comprises 1 part of Bifidobacterium animalis BPL1 and 50 parts of hypericin.
Example 11
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. Hypericin content in herba Hyperici perforati extract is 0.01%.
Example 12
A probiotic composition comprises 1 part of Bifidobacterium animalis BPL1 and 5 parts of herba Hyperici perforati extract. Hypericin content in herba Hyperici perforati extract is 0.05%.
Example 13
A probiotic composition comprises 5 parts of Bifidobacterium animalis BPL1 and 1 part of herba Hyperici perforati extract. Hypericin content in herba Hyperici perforati extract is 0.5%.
Example 14
A probiotic composition comprises 5 parts of Bifidobacterium animalis BPL1 and 1 part of herba Hyperici perforati extract. Hypericin content in herba Hyperici perforati extract is 1%.
Example 15
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. Hypericin content in herba Hyperici perforati extract is 0.01%. Bifidobacterium animalis BPL1 was 10 million/g of the composition.
Example 16
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. The bifidobacterium animalis BPL1 is a live bacterium, and the live bacterium is 100 hundred million/g of the composition.
Example 17
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. Bifidobacterium animalis BPL1 is a mixture of live bacteria and inactivated bacteria.
Example 18
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. The bifidobacterium animalis BPL1 is a mixture of live bacteria and inactivated bacteria, and the bacteria live in 500 hundred million/g.
Example 19
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. Bifidobacterium animalis BPL1 is a viable bacterium.
Example 20
A probiotic composition comprises Bifidobacterium animalis BPL1 1.8 parts, and herba Hyperici perforati extract 1 part. Bifidobacterium animalis BPL1 is a viable bacterium. Hypericin content in herba Hyperici perforati extract is 0.5%.
Example 21
A method for preparing probiotic composition comprises mixing Bifidobacterium animalis with herba Hyperici perforati extract. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 22
A method for preparing probiotic composition comprises mixing Bifidobacterium animalis with hypericin. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 23
Application of probiotic composition in antidepressant, health food, feed additive, and food additive is provided. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 24
Application of probiotic composition in medicine, health food, feed additive, and food additive for improving mood is provided. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 25
Application of probiotic composition in preparation of medicine, health food, feed additive, and food additive for reducing appetite is provided. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 26
A probiotic composition is used in medicine, health food, feed additive, and food additive for controlling body weight. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 27
A probiotic composition is used in medicine, health food, feed additive, and food additive for reducing fat accumulation. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 28
A probiotic composition is used in medicine, health food, feed additive, and food additive for inhibiting obesity. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 29
Application of probiotic composition in medicine, health food, feed additive, and food additive for improving insulin sensitivity is provided. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Example 30
Application of probiotic composition in medicine, health food, feed additive, and food additive for reducing blood lipid and blood pressure is provided. Probiotic composition: comprises Bifidobacterium animalis and Hypericum perforatum extract, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1. Bifidobacterium animalis BPL1 is 1.8 parts, and Hypericum perforatum extract is 1 part.
Experimental example 1
(1) An experimental model: the male SD rats are fed normally from weaning to 11 weeks, have room temperature of 20-26 ℃, relative humidity of 45% -65%, alternate light and shade for 12h, and keep good ventilation.
Rats were divided into 2 groups by weight, group 1 (n-10): male rats continued on a normal diet: energy is mainly derived from 70% carbohydrate, 20% protein, 10% fat; group 2(n ═ 40): a high fat diet was ingested with a caloric source of 55% fat, 29% carbohydrate, 16% protein. It is 2 weeks old. Group 1 was a placebo group, the fat rats in group 2 were divided into 4 groups, group a (n 10) was administered probiotic BPL 12.5 x 10^9CFU per day, group B (n 10) was administered hypericum perforatum extract (at a dose of 350 mg/kg) per day, group C (n 10) was administered probiotic BPL 12.5 x 10^9CFU per day-hypericum perforatum extract (at a dose of 350 mg/kg), group D (n 10) was a model control group, and no treatment was performed for 6 weeks. Group 2 all rats had a uniform diet and water, and probiotic bacteria and St.John's wort were mixed in 2ml of purified water and gavage was performed.
(2) Index detection
During the experiment, the food intake and the food spreading amount were recorded daily, the food remaining amount was recorded weekly, and the body weight was weighed 1 time per week. Then the rats are killed by carbon dioxide inhalation, perirenal fat and peritesticular fat at the same positions are dissected and taken out, the fat and the peritesticular fat are washed by normal saline, water is absorbed by filter paper, and the weight is weighed and recorded respectively. Serum was collected and measured for total serum cholesterol (TC), Triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) using a fully automatic biochemical analyzer.
From the food intake, food spill and food remaining recorded during the experiment, food intake was calculated according to equation (1):
food intake-food capacity-food consumption in bulk (unit: g)
Obesity index (Lee's index) the Lee's index was calculated according to equation (2) based on the body mass and body length of rats recorded during the experiment.
The perirenal, peritesticular and visceral fat coefficients are the ratio of perirenal fat mass, peritesticular fat mass, visceral fat mass (sum of perirenal fat mass and peritesticular fat mass) to rat body mass, respectively.
(3) Results and analysis of the experiments
TABLE 1 variation of body mass of rats in each group
The data show that the body mass of the model control group and the blank control group has significant difference (P is less than 0.05), and the high fat diet successfully induces the obese rats. The probiotics group, the hypericum perforatum group, the probiotics + hypericum perforatum group and the model control group have significant differences (P is less than 0.05), which shows that the probiotics BPL1 and the hypericum perforatum extract have the effect of reducing the weight of rats.
During intervention, the probiotic + hypericum perforatum combination group can significantly inhibit the increase in rat body mass caused by high fat diet compared with the hypericum perforatum group and the probiotic group. The probiotic BPL1 can influence the metabolism of tryptophan and promote the generation of serotonin, and can promote the hydrolysis and absorption of hypericin in the hypericum perforatum extract in the body, enhance the effect of the hypericum perforatum and maintain higher serotonin concentration, thereby achieving the effects of suppressing appetite and controlling weight.
TABLE 2 obesity index profiles of the groups of rats
| Body length/cm | Lee's index/%) | |
| Blank control group | 26.65 | 300.19 |
| Probiotic group | 26.40 | 312.84 |
| Hypericum perforatum group | 26.42 | 311.96 |
| Probiotic and hypericum perforatum group | 26.63 | 301.02 |
| Model control group | 26.30 | 318.11 |
The obesity index (Lee's index) result shows that the obesity index of the probiotic and hypericum perforatum group is obviously lower than that of the probiotic or hypericum perforatum group which is taken alone, which indicates that the probiotic BPL1 and hypericum perforatum are taken in combination, so that obesity and fat accumulation can be improved more obviously, the probiotic can have a relatively obvious promoting effect on metabolism and utilization of the hypericum perforatum, and the effect of reducing the fat accumulation is achieved by promoting the generation of serotonin, inhibiting the reabsorption and transformation of the serotonin, maintaining the concentration of the serotonin, increasing satiety and increasing satiety.
TABLE 3 Effect of visceral fat content in groups of rats
The data in table 3 demonstrate that the total visceral fat mass and coefficient for the probiotic group, the hypericum kwangsiense group, the probiotic group and the hypericum perforatum combination group are significantly lower than those of the model control group. There was a clear correlation with the body mass of the rats in each group. The Probiotic Strain, Lactobacillus brevis CECT8145 reduction Fat Content and modified Lipid Metabolism and antibiotic Response in Probiotic bacteria, reported that Probiotic bacteria CECT8145 can reduce Fat Content. The results for the probiotic group of the invention are consistent with this report. CN105849248B reports the use of CECT8145 probiotic in the treatment of overweight.
The hypericum perforatum extract and the probiotics act together, so that the fat accumulation of internal organs of a body is obviously controlled, the internal organ load is effectively reduced, the probiotics promote the hydrolysis and absorption of the hypericum perforatum, on one hand, the higher serotonin content is promoted, on the other hand, the heat production of adipose tissues is influenced through enzymatic reaction, and the reduction of the accumulation of subcutaneous fat and internal organ fat is facilitated.
TABLE 4 Effect on serum Biochemical indicators of obese rats
The probiotic and the hypericum perforatum extract are jointly ingested, the effect of reducing the contents of TG, TC and LDL-C is obvious, and the detection index is obviously superior to that of the group which ingests the probiotic or the hypericum perforatum alone. The hypericum perforatum and probiotics enter an organism, so that the content of serotonin can be increased by regulating tryptophan metabolism, the obesity is inhibited, the content of serum total cholesterol, triglyceride and low-density cholesterol can be reduced to a certain degree, and a serotonin receptor can be protected to promote the normal expression of the serotonin, so that the hypericum perforatum and probiotics have a certain prevention effect on induced symptoms related to the obesity, such as cardiovascular diseases and the like.
Tryptophan is converted into 5-HTP (5-hydroxytryptophan) by tryptophan hydroxylase (TRH) to generate 5-HT (5-hydroxytryptamine, serotonin), and 5-HT is mainly generated by enterochromaffin cells in the gastrointestinal tract and is used as an important gastrointestinal tract signal molecule which transmits signals from the intestinal tract to internal or external neurons, so that satiety can be effectively improved, appetite can be inhibited, and intestinal peristalsis and movement, secretion, vasodilatation and nutrient absorption can be influenced.
Effects of Bifidobacterium animalis subsp.Lacts (BPL1) filing in Children and Adolescents with Prader-Willi Syndrome A random crosslinked crossbar Trial, Nutrients 2020,12, 3123; doi:10.3390/nu12103123 discloses that Bifidobacterium animalis BPL1 can affect the tryptophan metabolic pathway, i.e. by activating the activity of tryptophan hydroxylase, the conversion of tryptophan to 5-HTP is accelerated, and 5-HT is generated.
10-year updated review, Phytotherapy research.2018; 1-16. hypericum perforatum has also been reported to be rich in naphthodianthrones, flavonoids and other substances and to inhibit the reabsorption of 5-HT; it also binds to and affects the expression of 5-HT1 receptors in the brain.
BPL1 can promote the hydrolysis of Hypericum perforatum to generate aglycone through glycosidase and other active substances and be metabolized and absorbed, so that the content of 5-HT is kept at a high safe level; thereby increasing the satiety of the human body, suppressing the appetite and playing the effect of losing weight and slimming. Sufficient 5-HT also can improve sleep disorder and relieve mood, and has certain effects in improving cognition and treating depression.
In addition, the extract of hypericum perforatum can activate AMPK signal through a dihydrolipoamide S-acetyltransferase (Dlat) target spot, stimulate adipose tissue to generate heat, and further achieve the effect of promoting weight loss.
It will be understood by those skilled in the art that, unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the prior art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
It should be understood that the above detailed description of the technical solution of the present invention with the help of preferred embodiments is illustrative and not restrictive. On the basis of reading the description of the invention, a person skilled in the art can modify the technical solutions described in the embodiments, or make equivalent substitutions for some technical features; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (9)
1. A probiotic composition, comprising Bifidobacterium animalis and Hypericum perforatum extract; or comprises Bifidobacterium animalis and hypericin.
2. The composition of claim 1, wherein the bifidobacterium animalis is bifidobacterium animalis BPL 1.
3. The composition according to claim 1, wherein the bifidobacterium animalis comprises inactivated bifidobacterium animalis and/or non-inactivated bifidobacterium animalis.
4. The composition of claim 1, wherein the composition comprises 1-100 parts of bifidobacterium animalis BPL1 and 1-100 parts of hypericum perforatum extract; further, 1-8 parts of bifidobacterium animalis BPL1 and 1-8 parts of hypericum perforatum extract; further, 1-5 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericum perforatum extract; further, 1-3 parts of bifidobacterium animalis BPL1 and 1-3 parts of hypericum perforatum extract; further, 1.8 parts of bifidobacterium animalis BPL1 and 1 part of hypericum perforatum extract;
and/or
Hypericin content in herba Hyperici perforati extract is greater than 0.01%, further greater than 0.1%, further greater than 0.3%, further greater than 1%, further greater than 10%;
and/or
The composition contains Bifidobacterium animalis BPL1 1-100 parts and hypericin 1-100 parts; further, 10-100 parts of bifidobacterium animalis BPL1 and 1-10 parts of hypericin; further, 50-100 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericin; further, the bifidobacterium animalis BPL1 is 60 parts, and hypericin is 1 part.
5. The composition of claim 1, wherein the bacterial viability of bifidobacteria in the composition is greater than 1, further greater than 10, further greater than 100, further greater than 500, further greater than 1000 parts per gram of the composition.
6. Use of a composition according to any one of claims 1 to 5 for the preparation of a product for alleviating or treating depression, a product for increasing mood, a product for reducing appetite, a product for reducing fat accumulation, a product for alleviating or treating hyperglycemia, a product for alleviating or treating hyperlipidemia, a product for alleviating or treating hypertension.
7. A product containing a probiotic composition, wherein the composition comprises Bifidobacterium animalis and Hypericum perforatum extract; or comprises Bifidobacterium animalis and hypericin.
8. The product according to claim 7, wherein the Bifidobacterium animalis is Bifidobacterium animalis BPL 1;
and/or
The bifidobacterium animalis contains inactivated bifidobacterium animalis and/or non-inactivated bifidobacterium animalis;
and/or
The composition comprises 1-100 parts of Bifidobacterium animalis BPL1 and 1-100 parts of Hypericum perforatum extract; further, 1-8 parts of bifidobacterium animalis BPL1 and 1-8 parts of hypericum perforatum extract; further, 1-5 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericum perforatum extract; further, 1-3 parts of bifidobacterium animalis BPL1 and 1-3 parts of hypericum perforatum extract; further, 1.8 parts of bifidobacterium animalis BPL1 and 1 part of hypericum perforatum extract;
and/or
Hypericin content in herba Hyperici perforati extract is greater than 0.01%, further greater than 0.1%, further greater than 0.3%, further greater than 1%, further greater than 10%;
and/or
The composition contains Bifidobacterium animalis BPL1 1-100 parts and hypericin 1-100 parts; further, 10-100 parts of bifidobacterium animalis BPL1 and 1-10 parts of hypericin; further, 50-100 parts of bifidobacterium animalis BPL1 and 1-5 parts of hypericin; further, 60 parts of bifidobacterium animalis BPL1 and 1 part of hypericin;
and/or
The bifidobacteria have a bacterial viability in the composition of greater than 1, further greater than 10, further greater than 100, further greater than 500, further greater than 1000 parts per gram of the composition.
9. A product containing probiotic composition is prepared by mixing Bifidobacterium animalis with herba Hyperici perforati extract and/or hypericin; optionally adding desired additives, and tabletting or encapsulating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111469754.8A CN114028444A (en) | 2021-12-03 | 2021-12-03 | Probiotic composition and application thereof in relieving depression and reducing fat accumulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111469754.8A CN114028444A (en) | 2021-12-03 | 2021-12-03 | Probiotic composition and application thereof in relieving depression and reducing fat accumulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114028444A true CN114028444A (en) | 2022-02-11 |
Family
ID=80139723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111469754.8A Pending CN114028444A (en) | 2021-12-03 | 2021-12-03 | Probiotic composition and application thereof in relieving depression and reducing fat accumulation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028444A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068508A (en) * | 2022-08-23 | 2022-09-20 | 哈尔滨美华生物技术股份有限公司 | Application of animal bifidobacterium in preparing medicament for preventing or treating depression |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056397A1 (en) * | 1997-06-12 | 1998-12-17 | Braswell A Glenn | Weight control composition comprising hypericum perforatum |
| US20160143963A1 (en) * | 2013-07-18 | 2016-05-26 | Biopolis, S.L. | Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases |
| CN110604749A (en) * | 2019-08-30 | 2019-12-24 | 北京农学院 | Bifidobacterium animalis and its use in controlling diabetes or hyperlipidemia, especially weight gain or obesity |
-
2021
- 2021-12-03 CN CN202111469754.8A patent/CN114028444A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056397A1 (en) * | 1997-06-12 | 1998-12-17 | Braswell A Glenn | Weight control composition comprising hypericum perforatum |
| US20160143963A1 (en) * | 2013-07-18 | 2016-05-26 | Biopolis, S.L. | Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases |
| CN110604749A (en) * | 2019-08-30 | 2019-12-24 | 北京农学院 | Bifidobacterium animalis and its use in controlling diabetes or hyperlipidemia, especially weight gain or obesity |
Non-Patent Citations (3)
| Title |
|---|
| MILICA MILUTINOVIC 等: "Plant Extracts Rich in Polyphenols as Potent Modulators in the Growth of Probiotic and Pathogenic Intestinal Microorganisms", 《FRONTIERS IN NUTRITION》 * |
| MONTSE AMAT-BOU 等: "Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial", 《NUTRIENTS》 * |
| 胡佳慧 等: "金丝桃素药理研究进展", 《药物生物技术》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068508A (en) * | 2022-08-23 | 2022-09-20 | 哈尔滨美华生物技术股份有限公司 | Application of animal bifidobacterium in preparing medicament for preventing or treating depression |
| CN115068508B (en) * | 2022-08-23 | 2022-11-25 | 哈尔滨美华生物技术股份有限公司 | Application of animal bifidobacterium in preparing medicament for preventing or treating depression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140227227A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
| CN104187709A (en) | Total nutrient formula food suitable for patients having obesity or fat-reducing operation | |
| CN107568736A (en) | Dealcoholic sobering-up medical science formula food | |
| JP6998613B2 (en) | A method for producing a composition for preventing, improving or treating the deterioration of intestinal function containing a bamboo shoot enzyme decomposition product or a bamboo shoot fermented product as an active ingredient. | |
| CN117487683A (en) | Probiotic composition with effects of resisting claustration, protecting stomach, promoting digestion and removing food retention and application thereof | |
| CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
| CN111249371A (en) | Composition for dispelling effects of alcohol and protecting liver and product | |
| CN112569323A (en) | Composition for dispelling effects of alcohol and protecting liver and application thereof | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| WO2010035675A1 (en) | Immunopotentiator or antiallergic agent | |
| CN104187613A (en) | Total-nutrient formulated food for patients with insomnia | |
| CN104509901A (en) | Nymphaea tetragona plant probiotic multi-flavor health beverage | |
| US20210353697A1 (en) | Composition comprising molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease | |
| CN114028444A (en) | Probiotic composition and application thereof in relieving depression and reducing fat accumulation | |
| CN110710660A (en) | Blood sugar lowering composition and dietary supplement containing bitter gourd powder | |
| JP2018516987A (en) | Pharmaceutical composition or health functional food for prevention and treatment of metabolic disease containing water extract of Aso as active ingredient | |
| KR101076223B1 (en) | Composition for treating and preventing obesity or hyperlipidemia comprising fermented oriental herb | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN117599140A (en) | Traditional Chinese medicine composition for reducing blood sugar, blood pressure and blood fat and preparation and application thereof | |
| CN108936607A (en) | Chronic Obstructive Pulmonary Disease full nutrition formula food | |
| CN103463407B (en) | Reason machine Jiangtang capsule | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| KR101626642B1 (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
| CN109925466A (en) | A kind of enteral microecological formulation and preparation method thereof adjusting man's diarrhea | |
| KR101923603B1 (en) | A composition for anti-obesity comprising green tea complex extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220211 |
|
| RJ01 | Rejection of invention patent application after publication |